Overview

Weight Loss With Exenatide Treatment

Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The investigators are conducting a study that will investigate the possible mechanisms of weight loss associated with exenatide treatment and the metabolic characteristics of high responders (i.e. subjects who achieve greater than 5% weight loss) to exenatide treatment. The investigators will also examine the magnitude and duration of weight loss among a cohort of high responders over 52 weeks of treatment, and at 3 and 6 months following treatment. Hypothesis: The mechanisms of weight loss with exenatide are not fully understood, and weight loss responses to exenatide are highly variable, possibly reflecting distinct metabolic parameters. By identifying and following a group of obese women who lose greater than 5% body weight after short-term exenatide treatment, the investigators can gain insights into the possible mechanisms of weight loss and assess long-term weight loss with this pharmacotherapeutic intervention.
Phase:
Phase 4
Details
Lead Sponsor:
Eleftheria Maratos-Flier
Jody Dushay
Collaborator:
AstraZeneca
Treatments:
Exenatide